Cytokinetics (NASDAQ:CYTK) and GT Biopharma (NASDAQ:GTBP) Head-To-Head Analysis

GT Biopharma (NASDAQ:GTBP) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Volatility and Risk

GT Biopharma has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.

Valuation & Earnings

This table compares GT Biopharma and Cytokinetics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$7.60 million	($7.00)	-0.33
Cytokinetics	$18.47 million	275.55	-$526.24 million	($5.26)	-8.17

GT Biopharma has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GT Biopharma and Cytokinetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-257.47%	-131.09%
Cytokinetics	-17,906.25%	N/A	-50.21%

Insider & Institutional Ownership

8.1% of GT Biopharma shares are held by institutional investors. 10.9% of GT Biopharma shares are held by insiders. Comparatively, 3.4% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for GT Biopharma and Cytokinetics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	0	0	1	1	3.50
Cytokinetics	0	2	15	1	2.94

GT Biopharma presently has a consensus price target of $11.00, suggesting a potential upside of 378.26%. Cytokinetics has a consensus price target of $82.00, suggesting a potential upside of 90.74%. Given GT Biopharma’s stronger consensus rating and higher possible upside, equities analysts plainly believe GT Biopharma is more favorable than Cytokinetics.

Summary

GT Biopharma beats Cytokinetics on 7 of the 13 factors compared between the two stocks.

About GT Biopharma

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.